Beschreibung
In order to be efficient as a therapeutic agent, CNS (central nervous system)-acting drugs must cross the blood-brain barrier (BBB) and enter into the brain. The existing and new biomedical approaches for the rational design of novel CNS-active nanocarriers and prodrugs to improve drug delivery play an important role by enhancing drug passive and active BBB transport. These drug delivery vectors can be applied for the treatment of many neurologic conditions, including Alzheimer's or Parkinson's diseases, neuroinfections (meningitis and encephalitis), hemorrhagic and ischemic stroke, and traumatic brain injury.
Autorenporträt
Dr. Shityakov is a senior researcher in the departments of Biomedicine and Bioinformatics at Würzburg University, Germany. His research interests include bioinformatics and rational drug design at the blood-brain barrier. His work has been published in high-impact-factor journals, including Nature, and presented at scientific conferences.
